{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:45:58Z","timestamp":1781163958010,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00262-021-03014-2","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T08:03:02Z","timestamp":1627027382000},"page":"627-636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody"],"prefix":"10.1007","volume":"71","author":[{"given":"Tamara","family":"Mateu-Albero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Ju\u00e1rez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Loscertales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Mol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Terr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Mu\u00f1oz-Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-9790","authenticated-orcid":false,"given":"Carlos","family":"Cuesta-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"3014_CR1","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1189\/jlb.2MR0815-380R","volume":"99","author":"MADF HauserLegler","year":"2016","unstructured":"HauserLegler MADF (2016) Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes. J Leukoc Biol 99:869\u2013882","journal-title":"J Leukoc Biol"},{"key":"3014_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.cytogfr.2013.03.001","volume":"24","author":"IYMDCEESR ComerfordHarata-LeeBuntingGregorKar","year":"2013","unstructured":"ComerfordHarata-LeeBuntingGregorKaraMcColl IYMDCEESR (2013) A myriad of functions and complex regulation of the CCR7\/CCL19\/CCL21 chemokine axis in the adaptive immune system. Cytokine Growth Factor Rev 24:269\u2013283","journal-title":"Cytokine Growth Factor Rev"},{"key":"3014_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nri2297","volume":"8","author":"RACA ForsterDavalos-MisslitzRot","year":"2008","unstructured":"ForsterDavalos-MisslitzRot RACA (2008) CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 8:362\u2013371","journal-title":"Nat Rev Immunol"},{"key":"3014_CR4","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1182\/blood.V99.8.2977","volume":"99","author":"KJKMJC TillLinZuzelCawley","year":"2002","unstructured":"TillLinZuzelCawley KJKMJC (2002) The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 99:2977\u20132984","journal-title":"Blood"},{"key":"3014_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1189\/jlb.1203652","volume":"76","author":"SNEMMMVGJMEC De Lopez-GiralQuintanaCabrerizoAlfonso","year":"2004","unstructured":"De Lopez-GiralQuintanaCabrerizoAlfonso-PerezSala-ValdesSoriaFernandez-RanadaFernandez-RuizMunoz SNEMMMVGJMEC (2004) Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 76:462\u2013471. https:\/\/doi.org\/10.1189\/jlb.1203652","journal-title":"J Leukoc Biol"},{"key":"3014_CR6","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1182\/blood-2005-04-1718","volume":"107","author":"SJCMA RichardsonMatthewsCatherwood","year":"2006","unstructured":"RichardsonMatthewsCatherwood SJCMA et al (2006) ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107:3584\u20133592","journal-title":"Blood"},{"key":"3014_CR7","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1182\/blood-2011-03-342436","volume":"118","author":"XJIW YanDozmorovLi","year":"2011","unstructured":"YanDozmorovLi XJIW et al (2011) Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood 118:5201\u20135210. https:\/\/doi.org\/10.1182\/blood-2011-03-342436","journal-title":"Blood"},{"key":"3014_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00262-015-1670-z","volume":"64","author":"CJABIJJFC Cuesta-MateosLoscertalesKreutzmanCo","year":"2015","unstructured":"Cuesta-MateosLoscertalesKreutzmanColom-FernandezPortero-SainzPerez-VillarTerronMunoz-Calleja CJABIJJFC (2015) Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. Cancer Immunol Immunother 64:665\u2013676","journal-title":"Cancer Immunol Immunother"},{"key":"3014_CR9","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1158\/0008-5472.CAN-15-0986","volume":"75","author":"LNV PatrussiCapitaniMartini","year":"2015","unstructured":"PatrussiCapitaniMartini LNV et al (2015) Enhanced chemokine receptor recycling and impaired S1P1 expression promote leukemic cell infiltration of lymph nodes in chronic lymphocytic leukemia. Cancer Res 75:4153\u20134163","journal-title":"Cancer Res"},{"key":"3014_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1182\/blood-2007-08-107300","volume":"111","author":"JMJAA Redondo-MunozJose TerolGarcia-Marco","year":"2008","unstructured":"Redondo-MunozJose TerolGarcia-MarcoGarcia-Pardo JMJAA (2008) Matrix metalloproteinase-9 is up-regulated by CCL21\/CCR7 interaction via extracellular signal-regulated kinase-1\/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood 111:383\u2013386","journal-title":"Blood"},{"key":"3014_CR11","first-page":"1020","volume":"118","author":"AAK RehmMensenSchradi","year":"2011","unstructured":"RehmMensenSchradi AAK et al (2011) Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood 118:1020\u20131033","journal-title":"Blood"},{"key":"3014_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/0008-5472.CAN-12-2749","volume":"73","author":"TEEM GirblHinterseerGrossinger","year":"2013","unstructured":"GirblHinterseerGrossinger TEEM et al (2013) CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility. Cancer Res 73:561\u2013570. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2749","journal-title":"Cancer Res"},{"key":"3014_CR13","doi-asserted-by":"publisher","first-page":"12048","DOI":"10.18632\/oncotarget.3660","volume":"6","author":"SEE GanghammerHuttererHinterseer","year":"2015","unstructured":"GanghammerHuttererHinterseer SEE et al (2015) CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21. Oncotarget 6:12048\u201312060. https:\/\/doi.org\/10.18632\/oncotarget.3660","journal-title":"Oncotarget"},{"key":"3014_CR14","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1096\/fj.201701452RR","volume":"32","author":"JMRDF LauferLyckLegler","year":"2018","unstructured":"LauferLyckLegler JMRDF (2018) ZAP70 expression enhances chemokine-driven chronic lymphocytic leukemia cell migration and arrest by valency regulation of integrins. FASEB J 32:4824\u20134835. https:\/\/doi.org\/10.1096\/fj.201701452RR","journal-title":"FASEB J"},{"key":"3014_CR15","doi-asserted-by":"publisher","first-page":"7081","DOI":"10.1038\/sj.onc.1210519","volume":"26","author":"MMPYFJPMA TicchioniEssafiJeandelDaviCassutoDe","year":"2007","unstructured":"TicchioniEssafiJeandelDaviCassutoDeckertBernard MMPYFJPMA (2007) Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene 26:7081\u20137091","journal-title":"Oncogene"},{"key":"3014_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.exphem.2010.05.003","volume":"38","author":"CSMVGJSAEJMC de Cuesta-MateosLopez-GiralAlfonso-Per","year":"2010","unstructured":"de Cuesta-MateosLopez-GiralAlfonso-PerezSoriaLoscertalesGuasch-VidalBeltranZapataMunoz-Calleja CSMVGJSAEJMC (2010) Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia. Exp Hematol 38:756\u2013764, 64 e1\u20134. https:\/\/doi.org\/10.1016\/j.exphem.2010.05.003","journal-title":"Exp Hematol"},{"key":"3014_CR17","doi-asserted-by":"publisher","first-page":"e19008-e","DOI":"10.1200\/JCO.2019.37.15_suppl.e19008","volume":"37","author":"CCJFW CuestaMunoz-CallegaLoscertalesTerro","year":"2019","unstructured":"CuestaMunoz-CallegaLoscertalesTerronMol CCJFW (2019) CAP-100: First-in-class antibody for CCR7+ hematological malignancies. J Clinic Oncol 37:e19008-e. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e19008","journal-title":"J Clinic Oncol"},{"key":"3014_CR18","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1158\/1538-7445.AM2019-4849","volume":"79","author":"CCJFW Cuesta-MateosMu\u00f1oz-CallejaLoscertal","year":"2019","unstructured":"Cuesta-MateosMu\u00f1oz-CallejaLoscertalesTerronMol CCJFW (2019) Abstract 4849: CAP-100: first-in-class anti-CCR7 antibody for CLL. Cancer Res 79:4849. https:\/\/doi.org\/10.1158\/1538-7445.AM2019-4849","journal-title":"Cancer Res"},{"key":"3014_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00277-017-2973-2","volume":"96","author":"VA KaurSwami","year":"2017","unstructured":"KaurSwami VA (2017) Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Ann Hematol 96:1175\u20131184. https:\/\/doi.org\/10.1007\/s00277-017-2973-2","journal-title":"Ann Hematol"},{"key":"3014_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","volume":"74","author":"FM CameronSanford","year":"2014","unstructured":"CameronSanford FM (2014) Ibrutinib: first global approval. Drugs 74:263\u2013271. https:\/\/doi.org\/10.1007\/s40265-014-0178-8","journal-title":"Drugs"},{"key":"3014_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1182\/asheducation-2018.1.248","volume":"2018","author":"JR Brown","year":"2018","unstructured":"Brown JR (2018) Relapsed CLL: sequencing, combinations, and novel agents. Hematology Am Soc Hematol Educ Program 2018:248\u2013255. https:\/\/doi.org\/10.1182\/asheducation-2018.1.248","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3014_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/asheducation-2018.1.242","volume":"2018","author":"N Jain","year":"2018","unstructured":"Jain N (2018) Selecting Frontline Therapy for CLL in 2018. Hematology Am Soc Hematol Educ Program 2018:242\u2013247. https:\/\/doi.org\/10.1182\/asheducation-2018.1.242","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3014_CR23","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"MBDD HallekChesonCatovsky","year":"2018","unstructured":"HallekChesonCatovsky MBDD et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745\u20132760. https:\/\/doi.org\/10.1182\/blood-2017-09-806398","journal-title":"Blood"},{"key":"3014_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJASG MaddocksRuppertLozanski","year":"2015","unstructured":"MaddocksRuppertLozanski KJASG et al (2015) Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol 1:80\u201387. https:\/\/doi.org\/10.1001\/jamaoncol.2014.218","journal-title":"JAMA Oncol"},{"key":"3014_CR25","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/ajh.25261","volume":"93","author":"ARLEJN MatoRoekerAllan","year":"2018","unstructured":"MatoRoekerAllan ARLEJN et al (2018) Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol 93:1394\u20131401. https:\/\/doi.org\/10.1002\/ajh.25261","journal-title":"Am J Hematol"},{"key":"3014_CR26","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MFACREBYJJSTM de RooijKuilGeestElderingChangBuggyPal","year":"2012","unstructured":"de RooijKuilGeestElderingChangBuggyPalsSpaargaren MFACREBYJJSTM (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119:2590\u20132594. https:\/\/doi.org\/10.1182\/blood-2011-11-390989","journal-title":"Blood"},{"key":"3014_CR27","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1189\/jlb.1105623","volume":"79","author":"MSNEJPC Alfonso-PerezLopez-GiralQuintanaLos","year":"2006","unstructured":"Alfonso-PerezLopez-GiralQuintanaLoscertalesMartin-JimenezMunoz MSNEJPC (2006) Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J Leukoc Biol 79:1157\u20131165. https:\/\/doi.org\/10.1189\/jlb.1105623","journal-title":"J Leukoc Biol"},{"key":"3014_CR28","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1182\/blood-2016-04-709519","volume":"128","author":"GMV PavlasovaBorskySeda","year":"2016","unstructured":"PavlasovaBorskySeda GMV et al (2016) Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4\/SDF-1 axis. Blood 128:1609\u20131613. https:\/\/doi.org\/10.1182\/blood-2016-04-709519","journal-title":"Blood"},{"key":"3014_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/1078-0432.CCR-15-1304","volume":"22","author":"MCUYS SkarzynskiNiemannLee","year":"2016","unstructured":"SkarzynskiNiemannLee MCUYS et al (2016) Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. Clinical Cancer Res Official J Am Assoc Cancer Res 22:86\u201395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1304","journal-title":"Clinical Cancer Res Official J Am Assoc Cancer Res"},{"key":"3014_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","volume":"12","author":"AMJDLJ ScottWolchokOld","year":"2012","unstructured":"ScottWolchokOld AMJDLJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278\u2013287","journal-title":"Nat Rev Cancer"},{"key":"3014_CR31","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41388-017-0066-2","volume":"37","author":"LNF PatrussiCapitaniCattaneo","year":"2018","unstructured":"PatrussiCapitaniCattaneo LNF et al (2018) p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from beta-arrestin at early endosomes. Oncogene 37:1534\u20131550. https:\/\/doi.org\/10.1038\/s41388-017-0066-2","journal-title":"Oncogene"},{"key":"3014_CR32","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-15-0781","volume":"21","author":"SEMRZJDHMA HermanMustafaJonesWongFarooquiWiest","year":"2015","unstructured":"HermanMustafaJonesWongFarooquiWiestner SEMRZJDHMA (2015) Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. Clinical Cancer Res Official J Am Assoc Cancer Res 21:4642\u20134651. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0781","journal-title":"Clinical Cancer Res Official J Am Assoc Cancer Res"},{"key":"3014_CR33","first-page":"4391","volume":"120","author":"NLL CapitaniPatrussiTrentin","year":"2012","unstructured":"CapitaniPatrussiTrentin NLL et al (2012) S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. Blood 120:4391\u20134399","journal-title":"Blood"},{"key":"3014_CR34","first-page":"4401","volume":"118","author":"ECMJPCNFM CalpeCodonyBaptistaAbrisquetaCarpio","year":"2011","unstructured":"CalpeCodonyBaptistaAbrisquetaCarpioPurroyBoschCrespo ECMJPCNFM (2011) ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1\/2 activation. Blood 118:4401\u20134410","journal-title":"Blood"},{"key":"3014_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.4049\/jimmunol.178.2.740","volume":"178","author":"RMJNWAAB HinmanBushanamNicholsSatterthwaite","year":"2007","unstructured":"HinmanBushanamNicholsSatterthwaite RMJNWAAB (2007) B cell receptor signaling down-regulates forkhead box transcription factor class O 1 mRNA expression via phosphatidylinositol 3-kinase and Bruton\u2019s tyrosine kinase. J Immunol 178:740\u2013747","journal-title":"J Immunol"},{"key":"3014_CR36","first-page":"31057","volume":"2017","author":"CAK WolfGardingFilarsky","year":"2017","unstructured":"WolfGardingFilarsky CAK et al (2017) NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer 2017:31057","journal-title":"Int J Cancer"},{"key":"3014_CR37","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1158\/1078-0432.CCR-04-0753","volume":"10","author":"ANFI RodriguezMartinezCamacho","year":"2004","unstructured":"RodriguezMartinezCamacho ANFI et al (2004) Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin Cancer Res 10:6796\u20136806","journal-title":"Clin Cancer Res"},{"key":"3014_CR38","doi-asserted-by":"publisher","first-page":"39218","DOI":"10.18632\/oncotarget.16836","volume":"8","author":"LNY PingDingShi","year":"2017","unstructured":"PingDingShi LNY et al (2017) The Bruton\u2019s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Oncotarget 8:39218\u201339229. https:\/\/doi.org\/10.18632\/oncotarget.16836","journal-title":"Oncotarget"},{"key":"3014_CR39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/leu.2015.316","volume":"30","author":"SSBYSTSBJAKRN ChenChangChangTongHamSherryBurgerRa","year":"2016","unstructured":"ChenChangChangTongHamSherryBurgerRaiChiorazzi SSBYSTSBJAKRN (2016) BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia 30:833\u2013843. https:\/\/doi.org\/10.1038\/leu.2015.316","journal-title":"Leukemia"},{"key":"3014_CR40","doi-asserted-by":"publisher","first-page":"9930","DOI":"10.18632\/oncotarget.2479","volume":"5","author":"LMYMSMJDJKMSA ZaitsevaMurrayShafatLawesMacEwanBow","year":"2014","unstructured":"ZaitsevaMurrayShafatLawesMacEwanBowlesRushworth LMYMSMJDJKMSA (2014) Ibrutinib inhibits SDF1\/CXCR4 mediated migration in AML. Oncotarget 5:9930\u20139938. https:\/\/doi.org\/10.18632\/oncotarget.2479","journal-title":"Oncotarget"},{"key":"3014_CR41","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.4049\/jimmunol.177.4.2314","volume":"177","author":"CMDF OteroGroettrupLegler","year":"2006","unstructured":"OteroGroettrupLegler CMDF (2006) Opposite fate of endocytosed CCR7 and its ligands: recycling versus degradation. J Immunol 177:2314\u20132323","journal-title":"J Immunol"},{"key":"3014_CR42","doi-asserted-by":"publisher","first-page":"45509","DOI":"10.1074\/jbc.C100527200","volume":"276","author":"AJL MarcheseBenovic","year":"2001","unstructured":"MarcheseBenovic AJL (2001) Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J Biol Chem 276:45509\u201345512","journal-title":"J Biol Chem"},{"key":"3014_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","volume":"26","author":"DJEARSJMRWSTM devan GorterBeulingKersseboomMiddendorpGi","year":"2007","unstructured":"devan GorterBeulingKersseboomMiddendorpGilsHendriksPalsSpaargaren DJEARSJMRWSTM (2007) Bruton\u2019s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 26:93\u2013104. https:\/\/doi.org\/10.1016\/j.immuni.2006.11.012","journal-title":"Immunity"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03014-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03014-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03014-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T16:06:30Z","timestamp":1645113990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03014-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3014"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03014-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CCM is an employee of Catapult Therapeutics and of Immunological and Medical Products (IMMED S.L.) and a shareholder in IMMED. JL has received honoraria from Abbvie, Janssen, BeiGene, and Astra-Zeneca. FT and WM are managing directors of Catapult Therapeutics, and FT is CEO of IMMED.S.L. and a shareholder in the same company and Catapult Therapeutics. CMC is a consultant for IMMED S.L., held a patent for the use of therapeutic antibodies targeting CCR7 in cancer and has received research funds from IMMED.S.L. and Catapult Therapeutics. She also holds shares in IMMED S.L. RJS is an employee of IMMED S.L. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The clinical study was performed in accordance with the principles of the Declaration of Helsinki and was approved and supervised by the Ethics Committee of Hospital Universitario de la Princesa (PI-352). Written informed consent was obtained from each patient before they entered the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from each patient before they entered the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}